CDKN2A Antibody | 4211

CDKN2A Antibody | 4211 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse, Rat

Homology: N/A

Immunogen: Anti-CDKN2A antibody (4211) was raised against a peptide corresponding to 18 amino acids near the amino terminus of human CDKN2A.
The immunogen is located within the first 50 amino acids of CDKN2A.

Research Area: Signal Transduction, Homeostasis, Cancer

Tested Application: E, WB, IHC-P, IF

Application: WB: 1 - 4 μg/mL; IHC-P: 5 - 10 μg/mL; IF: 20 μg/mL.
Antibody validated: Western Blot in human and mouse samples; Immunohistochemistry in human and rat samples; Immunofluorescence in human and rat samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1201 - HeLa Cell Lysate

Positive Control 2: Cat. No. 1211 - HepG2 Cell Lysate

Positive Control 3: Cat. No. 1411 - Mouse Colon Tissue Lysate

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 17 kDa
Observed: 17 kDa

Validation:

KO Validation (Figure 1) : Anti-CDKN2A antibodies (4211) specificity was further verified by CDKN2A specific knockout. CDKN2A signal was not detected in CDKN2A knockout 293 cells as compared to that in control wild type cells.

Independent Antibody Validation in Cell lines (Figure 2) shows similar CDKN2A expression profile in human cell lines detected by two independent anti-CDKN2A antibodies that recognize different epitopes, 4211 against N-terminus domain and 8975 against the C-terminus domain.  CDKN2A proteins are detected only in 293, HeLa and HepG2 cell lines by the two independent antibodies. 

Recombinant Protein Test (Figure 3) shows that anti-CDKN2A antibody (4211) detects human recombinant CDKN2A protein that contains the amino acids of 4211 antigenic peptide.

Isoform: Human CDKN2A has 6 isoforms, including isoform 1 (156aa, 17kD) , isoform 2 (105aa, 11kD) , isoform 3 (116aa, 12kD) , isoform 5 (167aa, 18kD) , isoform tumor suppressor ARF (132aa, 14kD) and isoform smARF (85aa, 9kD) . Mouse CDKN2A has 4 isoforms, including isoform 1 (168aa, 18kD) , isoform 2 (125aa, 14kD) , isoform tumor suppressor ARF (169aa, 19kD) and isoform smARF (125aa, 14kD) . Rat CDKN2A has two isoforms, including isoform 1 (159aa, 17kD) and isoform ARF (160aa, 17kD) . 4211 can detect only human isoforms 1, 3 and 5, mouse isoform 1 and rat isoform 1.

Purification: CDKN2A Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: CDKN2A Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: CDKN2A antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: CDKN2A Antibody: ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P19ARF, P16INK4, P16INK4A, P16-INK4A, Cyclin-dependent kinase 4 inhibitor A

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: CDKN2A Antibody: The CDKN2A locus gives rise to 2 distinct transcripts from different promoters. The transcripts have been designated p16 (INK4A) and p14 (ARF) . This chromosomal region undergoes a number of inversions, translocations, heterozygous deletions, and homozygous deletions in a variety of malignant cell lines including those from glioma, non-small cell lung cancer, leukemia, and melanoma. Deletion of the region containing CDKN2A is found in more than half of all melanoma cell lines. Conversely, transfection of CDKN2A suppressed the growth of two independent mesothelioma cell lines, suggesting that inactivation of the CDKN2 gene is an essential step in the etiology of malignant mesotheliomas. CDKN2A induces a G1 cell cycle arrest by inhibiting the phosphorylation of the Rb protein by the cyclin-dependent kinases CDK4 and CDK6. CDKN2A is expressed as at least three distinct isoforms.